Drug intelligence / Profile preview

RT-3000

Development stage: Unknown
Lead developer: RenaissThera
Modality: Small Molecules
Administration: Oral

Overview

RT-3000 is an investigational oral small molecule agonist of the Gastric Inhibitory Polypeptide Receptor (GIPR), currently being developed by RenaissThera for the treatment of obesity. As part of a pipeline of oral incretin mimetics, RT-3000 is designed to provide a potent, orally bioavailable alternative to injectable peptide-based therapies. By activating the GIP receptor, the drug aims to leverage the metabolic benefits of GIP signaling, which includes the regulation of energy homeostasis, lipid metabolism, and insulin sensitivity. RT-3000 is currently in Phase 2 clinical development, targeting significant weight reduction and improved metabolic health in patients with obesity.

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on RT-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT-3000.

Explore the full profile